Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Khanolkar

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
QJM : Monthly Journal of the Association of Physicians|March 21, 2008
The diabetic footM P Khanolkar, S C Bain, J W Stephens
Atherosclerosis|September 4, 2007
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activationM P Khanolkar, R H K Morris, A W Thomas, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
QJM : Monthly Journal of the Association of Physicians|March 21, 2008
The diabetic footM P Khanolkar, S C Bain, J W Stephens
Atherosclerosis|September 4, 2007
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activationM P Khanolkar, R H K Morris, A W Thomas, et al.
Pageof 1